Coordinates: 23°04′26″N 82°27′08″W / 23.0738°N 82.4523°W / 23.0738; -82.4523

Center for Genetic Engineering and Biotechnology

From WikiProjectMed
Jump to navigation Jump to search
Center for Genetic Engineering and Biotechnology

Offices of the CIGB
Research institute overview
FormedJuly 1, 1985 (1985-07-01)
Jurisdiction Cuba
HeadquartersAvenida 31 No. 15802, Havana, Cuba
23°04′26″N 82°27′08″W / 23.0738°N 82.4523°W / 23.0738; -82.4523
Websitewww.cigb.edu.cu

The Center for Genetic Engineering and Biotechnology (Spanish: Centro de Ingeniería Genética y Biotecnología, CIGB) is a research institute in Havana, Cuba.

Founding

In 1982, the United Nations Industrial Development Organization (UNIDO) offered grant funding via a competitive application process to facilitate biotechnology development in the Third World.[1]: 132  Cuba sought, but did not receive funding, which instead was awarded to a joint project proposed by India and Italy.[1]: 132  Cuba nonetheless proceeded with the development of a biotechnology research institution using its own funds, CIGB.[1]: 132 

Activity

In 2006, CIGB developed the Heberprot-P, which is used to treat foot ulcers.[2] Its use results in rapid wound healing and a 75% decrease in amputations among diabetics with foot ulcers.[2]

As of 2017, CIGB had 1,600 employees and sold 21 products internationally.[1]: 138 

As of 2020, CIGB had two joint ventures with China.[1]: 143 

It is responsible for creating the Abdala vaccine.[3][4][5]

The Centre developed the COVID-19 vaccine Mambisa, which is in the final stages of clinical trials.[6]

See also

References

  1. ^ a b c d e Yaffe, Helen (2020). We Are Cuba! How a Revolutionary People Have Survived in a Post-Soviet World (hardcover ed.). USA: Yale University Press. ISBN 978-0-300-23003-1.
  2. ^ a b "UA Health Sciences Researchers Look to Collaborate With Cuba on Diabetic Wound Therapy | Department of Medicine". deptmedicine.arizona.edu. Retrieved 2023-12-27.
  3. ^ "Cuba's COVID vaccine rivals BioNTech-Pfizer, Moderna". DW.COM. 2021-06-27. Retrieved 2021-06-28.
  4. ^ "ABDALA Clinical Study - Phase III". rpcec.sld.cu. Registro Público Cubano de Ensayos Clínicos. Archived from the original on 2021-03-20. Retrieved March 22, 2021.
  5. ^ "ABDALA Clinical Study". rpcec.sld.cu. Registro Público Cubano de Ensayos Clínicos. Archived from the original on 2021-01-22. Retrieved March 22, 2021.
  6. ^ Sánchez, Liz Conde (7 April 2022). "How is Mambisa progressing on the road to authorization as an anti-COVID-19 vaccine?". en.granma.cu. Retrieved 6 May 2022.

External links


Stub icon

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.

Stub icon

This Cuba-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://mdwiki.org/wiki/Center_for_Genetic_Engineering_and_Biotechnology"